

SGLT2 Inhibitor Patient Information

What are SGLT2 Inhibitors?

SGLT2 inhibitors are drugs that protect the heart and help the heart to function better. They also help to control blood sugar and can protect the kidneys.

You may be prescribed an SGLT2 inhibitors to help

- Treat heart failure
- Treat type 2 diabetes
- Protect kidneys from leaking important proteins.

Benefits of SGLT2 Inhibitors

When using this medication as directed by your healthcare provider, SGLT2 inhibitors can:

- Slow heart failure progression
- Improve quality of life
- Prolong life
- Reduce risk of hospitalization
- Lower blood sugar (sometimes)
- Help you lose weight
- Reduce risk of some liver diseases
- Protect the kidneys.

Side Effects

Most individuals taking SGLT2 inhibitors do not experience concerning side effects. Your other health issues and medications influence what side effects could develop. Please discuss side effects to watch for with your healthcare provider.

Otherwise, please connect with your community pharmacist.

Common SGLT2 Inhibitors

- [□ Dapagliflozin \(Farxiga\)](#)
- [□ Empagliflozin \(Jardiance\)](#)
- [□ Canagliflozin \(Invokana\)](#)

Additional Resources

Medication Tips

Please reach out to your healthcare provider if you have any questions or concerns about your condition and the use of this medication. This may include members of your heart failure team.

If you are concerned about dehydration due to severe illness, diarrhea or vomiting it is usually recommended that these medicines are stopped until you are feeling better. This should be reviewed with your heart failure team.

If you experience bladder infections or yeast infections while on these medications please connect with your heart failure team to discuss a plan.

Your heart failure team

- Best Care phone contact
- Telehome Monitoring contact
- Community paramedic contact
- Family Doctor or Nurse Practitioner
- Heart failure clinic phone contact

Resource written by Deo Narayan (Queen's University) and Danielle Goodman (Western University)

Education grant provided by Continuing Professional Development, Schulich School of Medicine and Dentistry, Western University

Approved by Huron Perth and Area Heart Failure Working Group

March 2024

Updated: Sept 2022